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Aortic stiffness is a key characteristic of arterial aging and a strong predictor of cardiovascular events.1–4 An exagger-
ated blood pressure response during daily activities, producing 
increased load on the heart and blood vessels, is among the 
pathogenic consequences of an inelastic aorta.5 In view of the 
important pathophysiological role of aortic stiffness, the modi-
fiable determinants of stiffening need to be better understood by 
studying longitudinal changes. As a consequence of the obesity 
epidemic, general and central adiposity are highly prevalent. 
Both are associated with aortic stiffness6–9 and increased risk of 
cardiovascular disease.10,11 Sparse longitudinal evidence to date 
leaves uncertainty about the role of adiposity in later midlife in 
progression of aortic stiffness.12–15
In this context, we assessed the effect of adipos-
ity on aortic stiffening in a large longitudinal study with 
2 measurements of carotid-femoral pulse wave veloc-
ity (PWV) 4 years apart, using applanation tonometry. We 
compared prospective effects of differing measures: general 
adiposity by body mass index (BMI), central adiposity by 
waist circumference and waist:hip ratio, and fat mass per-
cent by body impedance. We considered the effect of con-
current change in adiposity. After stratifying the cohort into 
metabolically healthy and unhealthy participants, defined 
according to National Cholesterol Education Program Adult 
Treatment Panel-III criteria, excluding waist circumference, 
we examined the effects of adiposity on aortic stiffening.16 
We examined the biological pathways linking adiposity with 
aortic stiffening in a series of models controlling for chronic 
disease, use of medication, heart rate, metabolic risk factors, 
and markers of inflammation.
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Methods
Study Population and Design
The Whitehall II study is a longitudinal study of 10 308 male and 
female civil servants (initially aged 35–55 years) recruited in 1985 to 
1988 on the basis of staff lists from offices located in central London. 
The response rate was 73%. Details of the cohort investigations and 
loss to follow-up have been published.17 The cohort has been fol-
lowed with clinical examinations every 4 to 5 years. Research Ethics 
Committee approval and written informed consent from each partici-
pant were obtained at each study phase. The present sample included 
those who had a PWV measurement at the 2008 to 2009 (n=4347) or 
2012 to 2013 (n=4344) assessments, screened at our clinic or at home 
(20% of participants) using the same protocol. After exclusion of 65 
PWV observations with missing covariates, the analyses used 8636 
measurements from 5172 participants, of whom 3454 provided PWV 
measurements on both occasions.
Measures
Aortic PWV was assessed between carotid and femoral sites using 
applanation tonometry (SphygmoCor; Atcor Medical, Australia). We 
used standard protocols to diagnose vascular disease and diabetes 
mellitus and to assess antihypertensive medication use. Risk factors 
were measured in 2003 to 2004 and 2008 to 2009 to provide mean 
exposure in the 5 years before baseline PWV assessment in 2008 
to 2009. Description of measurement protocols is available in the 
online-only Data Supplement.
Statistical Analysis
Distributions of adiposity measures were categorized in sex-specific 
thirds and standardized units. Linear mixed models were used to esti-
mate the relationship of adiposity with PWV in 2008 to 2009 and change 
in PWV between 2008 to 2009 and 2012 to 2013. These models use all 
available PWV data and account for correlation between repeated mea-
sures within individuals. We fitted the intercept and slope with time as 
random effects for individual differences in PWV at baseline and rate 
of change over follow-up. The main effect for adiposity estimates the 
effect on PWV at baseline (2008–2009), whereas the adiposity×time 
interaction term estimates the effect of adiposity on change in PWV 
between 2008 to 2009 and 2012 to 2013 as a 5-year change.
Models were adjusted for age, sex, ethnic group, and mean arterial 
pressure at the time of PWV measurement. Change in PWV by third 
of each adiposity measure and per 1SD increment in adiposity was 
estimated. PWV changes were estimated separately among those who 
were metabolically healthy and unhealthy according to ATP-III criteria 
excluding waist circumference.16 Further models additionally adjusted 
for (1) chronic disease and antihypertensive medication, (2) heart rate, 
(3) serum triglycerides, high-density lipoprotein, fasting glucose, and 
hemoglobin A1c, (4) C-reactive protein and interleukin-6, and (5) 
all factors. Main analyses using logarithmically transformed PWV, 
in place of PWV, produced similar strength of associations with adi-
posity. We conducted a sensitivity analysis to examine potential bias 
arising from change in central adiposity over the follow-up period.18 
We calculated path length at follow-up adjusted for the association 
between change in waist circumference and change in measured aortic 
path length. Adjustment was based on a sex-specific regression model 
of change in path length against change in waist circumference. The 
path length was adjusted to remove the effect of change in waist cir-
cumference on path length in each individual. We used data from a 
published meta-analysis4 to estimate change in cardiovascular disease 
risk resulting from increased log PWV because of a 1SD higher BMI 
and expressed this change according to Wormser et al11 to estimate the 
proportion of this increase mediated through PWV.
Results
The mean age of participants was 65.5 years, and they were 
predominantly of white ethnic origin. Fewer than 20% had 
prevalent chronic disease, and around one third were taking 
antihypertensive medication. Mean BMI was 26.5 kg/m2. 
Detailed characteristics of the sample at baseline are shown in 
Table S1 in the online-only Data Supplement.
Age, ethnicity, and disease status were associated with base-
line PWV after adjustment for mean arterial pressure (Table 
S2). Older age, disease status, and antihypertensive medication 
use were associated with greater increases in PWV over follow-
up. In analyses adjusted for covariates (Table S3), the mean 
difference in baseline PWV expressed as proportion of SD of 
PWV in 2008 to 2009 across each third of mean BMI, waist 
circumference, waist:hip ratio, and fat mass percent was 11%, 
16%, 18%, and 13%, respectively. There was a linear associa-
tion between each measure of adiposity and PWV change (all 
P<0.001). The size of increase in PWV was strongly related to 
World Health Organization BMI categories (Figure 1).
The influence of risk factor status on longitudinal change 
in PWV according to the degree of adiposity was examined in 
metabolically healthy and unhealthy participants, defined using 
the Adult Treatment Panel-III definition, excluding waist cir-
cumference (Figure 2). There was a significant 5-year increase 
in PWV according to all adiposity measures, based on tests for 
linear trend, with similar trends in the metabolically unhealthy 
and healthy groups. There was evidence of departure from lin-
earity for the longitudinal effect of waist circumference.
Table shows the cross-sectional difference and change in 
PWV associated with adiposity measures after controlling 
separately for disease status and antihypertensive medication, 
heart rate, metabolic factors, inflammatory markers, and all 
of the foregoing. The standardized effect of each adiposity 
measure on PWV change over the follow-up in the maximally 
adjusted model was similar in size and was reduced by one 
quarter to one third compared with the minimally adjusted 
model (model 1). Sensitivity analysis with additional adjust-
ment for the association between change in waist circum-
ference and change in measured aortic path length between 
baseline and follow-up confirmed the stability of our findings 
Figure 1. Pulse wave velocity (PWV) change per 5 years (m/s) 
from age 60 by World Health Organization body mass index 
(BMI) groups in men and women; 8661 person-observations. 
Estimates adjusted for age, sex, ethnicity, and mean arterial 
pressure. P value for trend across groups is <0.001. P value for 
departure from linear trend is 0.16. Underweight/normal weight, 
n=2065; overweight, n=2268; and obese, n=856.
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(Table S4). Minimally adjusted models using baseline path 
length to calculate the follow-up PWV again confirmed our 
findings (Table S5).
The effects of previous adiposity, based on the 4 measures, 
were not confounded by changes in adiposity across (concur-
rent with) the PWV assessments or by changes in available 
risk factors (triglyceride, high-density lipoprotein, fasting 
glucose, hemoglobin A1c, and heart rate; Table S6). Effect 
modification because of degree of change in adiposity across 
PWV observations was not evident when observations were 
stratified at respective medians (Table S7). An effect of previ-
ous adiposity level on increase in PWV was observed in all 
subgroups. The effect of previous BMI, waist circumference, 
and fat mass percent on PWV change was larger in hyperten-
sive than normotensive participants (Table S8). There was no 
effect modification according to sex or diabetic status.
Based on meta-analytic findings, 12% of the projected 
increment in cardiovascular disease risk resulting from higher 
BMI was because of increased PWV.
Discussion
Principal Findings
This large longitudinal study of men and women shows that 
adiposity in later midlife predicts accelerated progression of 
aortic stiffness. Progression was based on 2 assessments, in 
2008 to 2009 and 2012 to 2013, by carotid-femoral appla-
nation tonometry using a standard protocol. The stiffening 
effect of adiposity was similar in those defined as meta-
bolically healthy and metabolically unhealthy according 
to Adult Treatment Panel-III criteria. Stiffening was inde-
pendent of change in adiposity, glycemia, and lipid levels 
between PWV assessments. Taking account of chronic dis-
ease status, use of medication, heart rate, metabolic health, 
and markers of inflammation, the robust association with 
increase in PWV over the follow-up suggests that adiposity 
is an important risk factor for aortic stiffening. Our novel 
longitudinal findings have clinical and public health signifi-
cance for older people.
We studied 4 noninvasive measures of adiposity. Observed 
associations with PWV increase were similar whichever mea-
sure was used. Tests for nonlinearity suggested that increase 
in PWV during the follow-up was linked with high rather than 
intermediate levels of central adiposity. Some cross-sectional 
studies6,7,9,19 have identified central or visceral adiposity as 
more strongly correlated than general adiposity with PWV. 
A longitudinal study showed that clustering of metabolic 
risk factors was associated with PWV increase.13 The present 
larger study shows that progression tended to be faster (men: 
0.25 m/s per 5 years; P=0.002 and women: 0.36 m/s per 5 
years; P=0.02) in those who were metabolically unhealthy 
regardless of degree of adiposity. Nonetheless, all adiposity 
measures were robust predictors of accelerated aortic stiff-
ening after adjustment for metabolic and inflammatory risk 
factors.
Research in Context
The determinants of aortic stiffening have been under active 
investigation for 3 decades. A cross-sectional study in the 
1980s in China identified urbanicity, high salt intake, and 
hypertension, as well as age, as risk factors for aortic stiff-
ness.1 The association between prevalence of hypertension and 
arterial stiffness within this population was accompanied by 
low prevalence of atherosclerosis and low serum cholesterol 
levels. Since then, studies in general population samples have 
found associations between PWV and lipid, glycemic, and 
inflammatory risk factors,8,20,21 as well as with obesity.6,7,9,19 
These cross-sectional findings are inconsistent and temporal-
ity could not be examined.
The hypothesis that hypertension is the primary factor 
and aortic stiffness is secondary1,8 is challenged by recent 
longitudinal studies of disease-free nonhypertensive older 
adults. These data show that an inelastic aorta predicts inci-
dent hypertension and the degree of subsequent blood pres-
sure rise.14,22,23 Notably, in the Framingham Offspring Study, 
high PWV predicted incident hypertension, but initial blood 
pressure did not predict PWV at follow-up.14 Because there 
may be a 2-way association between blood pressure and 
PWV,15 we controlled for mean arterial pressure, to control 
for aortic distension during PWV determination but not for 
systolic, diastolic, or pulse pressure to avoid overadjust-
ment. In this study, previous adiposity was associated with a 
larger increase in PWV in hypertensive than in normotensive 
participants.
Figure 2. Pulse wave velocity (PWV) change per 5 years (m/s) 
from age 60 by thirds of adiposity in men and women among 
metabolically healthy (A) and unhealthy (B) participants (Adult 
Treatment Panel-III definition excluding waist circumference). 
Estimates adjusted for age, sex, ethnicity, and mean arterial 
pressure. P values for trend and departure from trend for 
metabolically healthy: body mass index (BMI), 0.02 and 0.56; 
waist, <0.001 and 0.01; waist:hip ratio (WHR), 0.03 and 0.48; 
fat percent, 0.02 and 0.56 and for metabolically unhealthy: BMI, 
0.001 and 0.07; waist, <0.001 and 0.04; WHR, 0.002 and 0.005; 
fat percent, 0.009 and 0.54.
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Implications
Aortic stiffness is an independent risk factor for incident 
hypertension, cardiovascular disease, and stroke,4,23 and it 
is associated with age-related physical2 and cognitive func-
tioning in older people.24 In addition to the known effects 
of raised BMI on cardiovascular disease risk,11,25 our pro-
spective longitudinal findings, based on >5000 partici-
pants, add to the evidence that excess adiposity and class 
I obesity are important determinants of the rate of arterial 
aging. On the basis of pooled analyses of incident cardio-
vascular disease, we estimate that 12% of the projected 
increase in cardiovascular disease because of raised BMI 
may be attributable to arterial stiffness in this age group.4,11 
The adiposity–arterial stiffening pathway may be a key 
target for efforts to compress morbidity and postpone func-
tional decline.26,27
Behavior change and pharmacological treatments are 
relevant potential interventions. Weight loss may lead to 
a useful reduction in PWV.28,29 Exercise capacity and aor-
tic stiffness are inversely associated.30 Short-term trials 
suggest that moderate aerobic exercise in midlife (fast 
walking, jogging, and swimming) reduces aortic PWV.31 
Paradoxically, regular resistance exercise (free weights 
and weight training machines) may increase PWV.32,33 
Reduction of adiposity-related risk factors with statin 
therapy34 may be effective in lowering PWV; however, 
the evidence is inconclusive.35 Antihypertensive drugs of 
various classes, including angiotensin-converting enzyme 
Table.  Association of Mean* Anthropometric Measures With Pulse Wave Velocity at Baseline (2008–2009)  
and 5-y Change in Pulse Wave Velocity
Anthropometric Measure Model Adjustments
Pulse Wave Velocity  
at Baseline (2008–2009)
Change in Pulse  
Wave Velocity (per 5 y)
Difference† (95% CI) P Value Increase† (95% CI) P Value
Body mass index Model 1‡ 0.20 (0.14 to 0.26) <0.001 0.21 (0.13 to 0.29) <0.001
Model 1+chronic disease, antihypertensive medication 0.14 (0.08 to 0.20) <0.001 0.19 (0.11 to 0.27) <0.001
Model 1+heart rate 0.14 (0.08 to 0.20) <0.001 0.21 (0.13 to 0.29) <0.001
Model 1+triglyceride, HDL, fasting glucose, HbA1
c
0.06 (0.00 to 0.12) 0.07 0.18 (0.10 to 0.27) <0.001
Model 1+CRP, IL-6 0.12 (0.05 to 0.18) <0.001 0.17 (0.08 to 0.25) <0.001
Model 1+all factors −0.03 (−0.10 to 0.04) 0.41 0.14 (0.05 to 0.24) 0.003
Waist circumference Model 1‡ 0.29 (0.24 to 0.35) <0.001 0.23 (0.16 to 0.31) <0.001
Model 1+chronic disease, antihypertensive medication 0.24 (0.18 to 0.30) <0.001 0.21 (0.14 to 0.29) <0.001
Model 1+heart rate 0.22 (0.17 to 0.27) <0.001 0.24 (0.16 to 0.31) <0.001
Model 1+triglyceride, HDL, fasting glucose, HbA1
c
0.16 (0.10 to 0.22) <0.001 0.22 (0.13 to 0.30) <0.001
Model 1+CRP, IL-6 0.24 (0.17 to 0.30) <0.001 0.18 (0.10 to 0.27) <0.001
Model 1+all factors 0.07 (0.00 to 0.14) 0.04 0.18 (0.08 to 0.27) <0.001
Waist:hip ratio Model 1‡ 0.34 (0.29 to 0.40) <0.001 0.20 (0.13 to 0.28) <0.001
Model 1+chronic disease, antihypertensive medication 0.29 (0.24 to 0.34) <0.001 0.19 (0.11 to 0.26) <0.001
Model 1+heart rate 0.27 (0.21 to 0.32) <0.001 0.21 (0.14 to 0.28) <0.001
Model 1+triglyceride, HDL, fasting glucose, HbA1
c
0.23 (0.17 to 0.29) <0.001 0.18 (0.10 to 0.26) <0.001
Model 1+CRP, IL-6 0.31 (0.25 to 0.37) <0.001 0.16 (0.08 to 0.24) <0.001
Model 1+all factors 0.15 (0.09 to 0.22) <0.001 0.16 (0.07 to 0.24) <0.001
Fat mass percent Model 1‡ 0.22 (0.16 to 0.27) <0.001 0.19 (0.12 to 0.26) <0.001
Model 1+chronic disease, antihypertensive medication 0.17 (0.12 to 0.23) <0.001 0.17 (0.10 to 0.25) <0.001
Model 1+heart rate 0.15 (0.10 to 0.21) <0.001 0.19 (0.12 to 0.26) <0.001
Model 1+triglyceride, HDL, fasting glucose, HbA1
c
0.09 (0.03 to 0.15) <0.001 0.17 (0.09 to 0.25) <0.001
Model 1+CRP, IL-6 0.15 (0.09 to 0.21) <0.001 0.16 (0.07 to 0.24) <0.001
Model 1+all factors 0.02 (−0.05 to 0.08) 0.61 0.14 (0.05 to 0.23)  0.002
Analyses based on 8636 pulse wave velocity observations in 5172 participants except for fat mass percent: 8488 observations in 5031 participants. Models including 
CRP and IL-6 have 10% fewer observations. CRP indicates C-reactive protein; CI, confidence interval; HbA1
c
, hemoglobin A1c; HDL, high-density lipoprotein-cholesterol; 
and IL-6, interleukin-6.
*From assessments in 2003–2004 and 2008–2009.
†Cross-sectional difference or longitudinal increase in the outcome associated with 1 SD higher adiposity.
‡Model 1 is adjusted for age, sex, ethnic group, and mean arterial pressure at the time of the pulse wave velocity measurement.
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inhibitors, may prove valuable for lowering PWV in over-
weight and obese individuals.36,37
Mechanisms
The effects of adiposity in the 5 years before the baseline 
PWV assessment on aortic stiffening over the follow-up were 
little confounded by changes in adiposity and risk factor lev-
els across PWV assessments. As in a cross-sectional study, 
there were substantial reductions in the maximally adjusted 
associations of PWV with BMI and fat mass percent at base-
line because of risk factor clustering. In contrast, there were 
small attenuations in the longitudinal part of the model after 
these adjustments. The longitudinal findings suggest that met-
abolic and inflammatory processes contribute to the effects of 
adiposity on aortic stiffening. Higher adiposity is associated 
with higher heart rate, but this source of mechanical stress on 
the aortic wall did not seem to contribute to the pathophysi-
ologic process.38 Potential explanations for the unexplained 
longitudinal effect include a vicious circle of high adiposity, 
exercise intolerance, arterial stiffening, and physical inactiv-
ity,5 unmeasured pathways, such as that involving endothelial 
regulation39 and adipokines,40 and inadequate measurement of 
pathways represented in the maximally adjusted model.
Strengths and Weaknesses
This is the largest longitudinal study of adiposity and aortic 
PWV to date. We used the same gold-standard tonometry 
method at baseline and follow-up.41 At each contact phase, 
the average of 2 PWV measurements was used, with a third 
measurement used when, rarely, the difference between the 
first 2 was >0.5 m/s. This rigorous protocol contributed to the 
power of the study to detect change in PWV over the modest 
interval between measurement occasions. Determination of 
path length with a tape measure is the weakest element of the 
protocol because estimation of PWV involves a degree of sys-
tematic bias with respect to waist circumference.18 We found 
that there was an association between the modest change in 
waist circumference (SD, 5.2 cm) and change in the aortic 
path length over the follow-up period. However, our sensitiv-
ity analysis correcting for this bias showed that it did not dis-
tort the findings. Further analysis using path length at baseline 
to calculate both first and second PWV measurements circum-
vents the problem of change in adiposity and provides strong 
evidence that our longitudinal findings are robust. Separately, 
additional model adjustment for body height did not change 
the results (data not shown).
PWV was first measured in the cohort when the young-
est participants were aged 55. We therefore cannot contribute 
to the equivocal evidence concerning adiposity and PWV in 
younger adults.7,42 Vascular risk factor levels tend to be lower 
in our health-conscious occupational cohort than in the gen-
eral population; however, systematic comparison of risk factor 
effects on coronary risk between Whitehall II, Framingham, 
and the British Regional Heart Study shows that our etiologic 
estimates are generalizable.43
Perspectives
Aortic stiffness predicts cardiovascular events over and 
above standard risk factors. A high age-specific level of 
aortic stiffness is linked with poor aging-associated physical 
function, for example, slow-walk speed, poor lung function, 
and functional limitations. In this context, we measured 
carotid-femoral PWV on 2 occasions 4 years apart to show 
that degree of adiposity is a robust predictor of aortic stiffen-
ing. Adiposity was measured noninvasively in several ways 
(BMI, waist circumference, waist:hip ratio, and fat mass 
percent by body impedance) in the 5 years before baseline 
PWV assessment. Each adiposity measure predicted change 
in aortic PWV. Serial assessments of aortic stiffness may 
prove to be a valuable tool for monitoring vascular aging 
and tracking the effect of interventions to slow or reverse 
stiffening of the aorta.
Conclusions
Adiposity was a robust predictor of aortic stiffening in the 
presence and absence of co-occurring metabolic risk factors 
and inflammation. General and central obesity and fat mass 
percent were equally predictive of aortic stiffening in our 
study sample. Adiposity and associated metabolic risk factors 
are modifiable, suggesting that the adverse health and func-
tional consequences of aortic stiffening may be postponed or 
prevented.
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What Is New?
•	We collected 2 measures of carotid-femoral pulse wave velocity 4 years 
apart starting at the mean age of 66 years in a cohort of 5172 men and 
women.
•	We showed that the degree of adiposity in the 5 years before baseline 
assessment, whether measured as general obesity, central obesity, or 
fat mass percent, was a robust predictor of aortic stiffening.
•	Adiposity-associated stiffening of the aorta was observed in those who 
were metabolically healthy, as well as those who were not.
What Is Relevant?
•	The longitudinal relationship between aortic stiffening and hypertension 
remains unclear.
•	 Longitudinal analysis from the Framingham Offspring study suggests 
that aortic stiffness may be a precursor of hypertension in older people.
Summary
Adiposity may be an important and potentially modifiable determi-
nant of aortic stiffness and of incident hypertension in older people.
Novelty and Significance
